Media Center

24-03-2022

Publication in "Nature–Scientific Reports"

Epalinges, Switzerland, March 24, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, with title: “A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike”.

23-02-2022

Publication in "Frontiers in Immunology"

Epalinges, Switzerland, February 22, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Frontiers in Immunology with title: “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques against Mucosal SHIV challenges”

05-01-2021

Publication in "Clinical & Experimental Allergy"

Epalinges, January 5, 2021: Following two successful studies with its virosome platform, Mymetics announces the acceptance of its joint publication in the scientific journal Clinical & Experimental Allergy with Stallergenes Greer SA and Anergis SA, with the title: Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.

09-12-2020

Publication in "nature.com/npjvaccines"

Epalinges, January 31, 2020: Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

18-05-2020

Mymetics announces publication in npj - Vaccines “New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes”

Epalinges, Switzerland, 18 May 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Partner Journals “Vaccines” describing the results from a new GMP manufacturing process to obtain thermostable HIV-1 gp41 virosome vaccines under solid forms and various mucosal vaccination routes

25-04-2019

WORLD MALARIA DAY

Epalinges, Switzerland, April 25, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling human diseases has learned that there is inaccurate information in the public domain. Mymetics is dedicated to develop vaccines for life threatening and disabling diseases based on our virosome virus like particle platform.

26-07-2018

Material Incorrect Information in Public Domain

Epalinges, Switzerland, July 26, 2018 - Material Incorrect Information in Public Domain

26-06-2018

Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability

June 26th, 2018 - Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lipid A, 3D-PHAD® adjuvant.

11-10-2015

Particle based platforms for malaria vaccines

December 22nd, 2015 - Particle based malaria vaccines

10-04-2013

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

Respiratory syncytial virus (RSV) has been recognized as an important vaccine target for over 60 years; however, there is no vaccine on the market today.

13-03-2013

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

Respiratory syncytial virus infection remains a serious health problem, not only in infants but also in immunocompromised adults and the elderly. An effective and safe vaccine is not available due to several obstacles: non-replicating RSV vaccines may prime for excess Th2-type responses and enhanced respiratory disease (ERD) upon natural RSV infection of vaccine recipients.

12-02-2013

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

The human immunodeficiency virus type 1 (HIV-1) is mainly transmitted through sexual contact. To infect its host, HIV-1 employs its viral membrane surface trimeric envelope glycoprotein, composed of the receptor binding domain gp120 and the membrane anchored fusion protein subunit gp41.

15-05-2012

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice

Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant problem in elderly and immuno-compromised adults.

04-07-2011

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children

The development of an effective malaria vaccine is regarded as one cornerstone in the fight against this deadly disease and to achieve its eventual elimination.

25-02-2011

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

Human immunodeficiency virus (HIV)-1 is mainly transmitted mucosally during sexual intercourse. We therefore evaluated the protective efficacy of a vaccine active at mucosal sites.